Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities
Authors:
Open Access
- 4 April 2024
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (4) , e1645
Abstract
Background: Breast cancer remains a global health challenge, necessitating innovative therapeutic approaches. Immunomodulation and immunotherapy have emerged as promising strategies for breast cancer treatment. Engineered exosomes are the sort of exosomes modified with surface decoration and internal therapeutic molecules. Through suitable modifications, engineered exosomes exhibit the capability to overcome the limitations associated with traditional therapeutic approaches. This ability opens up novel avenues for the development of more effective, personalized, and minimally invasive interventions.Main body: In this comprehensive review, we explore the molecular insights and therapeutic potential of engineered exosomes in breast cancer. We discuss the strategies employed for exosome engineering and delve into their molecular mechanisms in reshaping the immune microenvironment of breast cancer.Conclusions: By elucidating the contribution of engineered exosomes to breast cancer immunomodulation, this review underscores the transformative potential of this emerging field for improving breast cancer therapy.Highlights: Surface modification of exosomes can improve the targeting specificity. The engineered exosome‐loaded immunomodulatory cargo regulates the tumour immune microenvironment. Engineered exosomes are involved in the immune regulation of breast cancer.Keywords
This publication has 109 references indexed in Scilit:
- Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular VesiclesAnnual Review of Cell and Developmental Biology, 2014
- Potential of Cancer Cell–Derived Exosomes in Clinical Application: A Review of Recent Research AdvancesClinical Therapeutics, 2014
- A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapyBiomaterials, 2014
- Targeting dendritic cells—why bother?Blood, 2013
- The significance of OX40 and OX40L to T‐cell biology and immune diseaseImmunological Reviews, 2009
- The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteinsNature, 2009
- The tumor‐draining lymph node as an immune‐privileged siteImmunological Reviews, 2006
- Lymphatic dissemination of tumour cells and the formation of micrometastasesThe Lancet Oncology, 2002
- Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-primingNature Medicine, 2001
- Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancerThe American Journal of Surgery, 1998